Volume | 192,483 |
|
|||||
News | (1) | ||||||
Day High | 1.39 | Low High |
|||||
Day Low | 1.29 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Personalis Inc | PSNL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.32 | 1.29 | 1.39 | 1.30 | 1.31 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,321 | 192,483 | $ 1.33 | $ 256,343 | - | 0.8906 - 2.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:28:00 | 10 | $ 1.27 | USD |
Personalis Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
65.66M | 50.50M | - | 73.48M | -108.3M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Personalis News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSNL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.42 | 1.42 | 1.26 | 1.32 | 108,073 | -0.12 | -8.45% |
1 Month | 1.62 | 1.85 | 1.26 | 1.51 | 216,111 | -0.32 | -19.75% |
3 Months | 1.72 | 1.85 | 1.18 | 1.47 | 246,661 | -0.42 | -24.42% |
6 Months | 1.51 | 2.38 | 1.12 | 1.58 | 385,889 | -0.21 | -13.91% |
1 Year | 1.83 | 2.60 | 0.8906 | 1.53 | 355,960 | -0.53 | -28.96% |
3 Years | 22.58 | 28.47 | 0.8906 | 6.80 | 426,010 | -21.28 | -94.24% |
5 Years | 23.70 | 53.46 | 0.8906 | 14.62 | 486,286 | -22.40 | -94.51% |
Personalis Description
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. |